Navigation Links
Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
Date:9/21/2007

DANBURY, Conn., Sept. 21 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that the Company has expanded its two ongoing pivotal Phase III clinical trials of VIAject(TM) into Europe. Clinical sites have been initiated in Germany and patient treatment has begun.

"We are expanding VIAject(TM)'s pivotal Phase III trials into Europe to support our planned European registration of VIAject(TM)," stated Dr. Solomon S. Steiner, Chairman and CEO of Biodel. "Given the worldwide prevalence of diabetes, we are determined to establish VIAject(TM) as a global solution. Evaluating VIAject(TM)'s therapeutic profile in European patients with Type 1 and Type 2 diabetes gives us the opportunity to demonstrate VIAject(TM)'s clinical outcomes across a more diverse patient population."

VIAject(TM) is currently undergoing two pivotal Phase III clinical studies. The two studies, one enrolling 400 Type 1 diabetic patients and the other enrolling 400 Type 2 diabetic patients, are comparing the effects of VIAject(TM) to Humulin(R) R, the leading recombinant human insulin. Both studies are open label and involve a treatment regimen that is six months in duration. Clinical endpoints of both trials include non-inferiority in terms of HbA1c levels and safety.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA- approved peptide drugs. The Company's lead product candidate, VIAject(TM), is a rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in Phase I clinical trials and tw
'/>"/>

SOURCE Biodel Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Biodel Inc. to Present VIAject Clinical Progress at the 2007 American Diabetes Association Meeting
2. PromegaExpress Expands Easy Access to Products with New Cabinet
3. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
4. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
5. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
6. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)...Today at ACG Annual Scientific Meeting -, ORLANDO...Pharmaceuticals, Inc. (formerly Microbia, Inc.) an...nounced the presentation of results from a Phase,2...y in 420 patients with,irritable bowel syndrome wi...cates that once- daily oral dosing of linaclotide,...
(Date:10/7/2008)... 7 /- Aerovance Inc. today reported,p... trial of its Aerovant,inhalation powder that demo...l irritancy following asthma patients, inhalation ...the highest of three doses investigated in,Aerovan...led to begin early,next year. Evidence gathered fr...
(Date:10/7/2008)...andomized Placebo-Controlled Phase II Study Shows ...l Survival., MOUNTAIN VIEW, California, October 7...luated the mature Phase II data from the,therapeut...that had been,obtained as part of the recently ent...e (NCI) in the US., The results from the Phase II...
(Date:10/7/2008)...rt Enrolled in Stage A of Trial Assessing Regimen ...and Paclitaxel -, TUSTIN, Calif., Oct. 7 /PRNewsw...(Nasdaq: PPHM ), a clinical stage biopharmaceutic...e treatment of cancer and,hepatitis C virus (HCV) ...nrollment in the first stage of a Phase II trial o...
Breaking Medicine Technology:Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5Data Show Aerovance's Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4Eularis Analyzes Most Effective Generics Defense Strategies With New Pharmaceutical Industry Report 23877 1Eularis Analyzes Most Effective Generics Defense Strategies With New Pharmaceutical Industry Report 23877 2Eularis Analyzes Most Effective Generics Defense Strategies With New Pharmaceutical Industry Report 23877 3Good Habits for School Success 23874 1Good Habits for School Success 23874 2iCRco Releases Clarity PACS the Clear Solution for Your Digital Radiology Imaging Needs 23869 1iCRco Releases Clarity PACS the Clear Solution for Your Digital Radiology Imaging Needs 23869 2Will New Technological Advances Offer Fresh Capabilities for Commercialization and Enhance BTL Investments 3F 6517 1Will New Technological Advances Offer Fresh Capabilities for Commercialization and Enhance BTL Investments 3F 6517 2Will New Technological Advances Offer Fresh Capabilities for Commercialization and Enhance BTL Investments 3F 6517 3
...he U.S.-based subsidiary of,Pharmexa A/S, presents...today at the Influenza Conference entitled, "Optio...to, Ontario, Canada. The,data show that a "univers...e responses can protect transgenic mice against,le...SOLM, Denmark, June 21, 2007-Pharmexa-Epimmune, th...
... India--(BUSINESS WIRE)--Jun 21, 2007,- The Instit...rmaceutical company, today announced that Phase 3 ...t, Paromomycin IM,Injection (Paromomycin), was pub...rnal of Medicine (NEJM). This clinical trial shows... and well suited,to curing visceral leishmaniasis ...
Other Medicine Technology:Pharmexa A/S (DK) - Pharmexa presents data from influenza program 2Research on New Treatment for Neglected Disease Published in The,New England Journal of Medicine 2Research on New Treatment for Neglected Disease Published in The,New England Journal of Medicine 3Research on New Treatment for Neglected Disease Published in The,New England Journal of Medicine 4
(Date:10/10/2008)... PARK CITY, Utah, Oct. 10 /PRNewswire/ -- NuVi...e management of Trace Life Sciences Inc.,(Trace), ... cyclotron,production facilities in Denton, Texas...., Indium-111, Iodine-123 and Thallium-201 used in,..., NuView Chairman and,CEO, stated that "We are con...
(Date:10/10/2008)... Coach Holly Warlick Teams Up with Legal and M...irst-Ever Cancer and Careers Seminar in,Knoxville,...ognition of National,Breast Cancer Awareness Month...e have joined forces with YWCA Knoxville, The Well...vocate Holly Warlick, University of Tennessee,wome...
(Date:10/10/2008)..., The Healthcare Technolo... Care , Exton, PA (PRWEB)... Valley Chapters of the national Healthcare Inform...ined forces to bring regional health information t...ional conference entitled The Healthcare Technolog...
(Date:10/10/2008)..., Boston, MABoston Medical Center (BMC) has recei...tional Institute on Aging (NIA) to fund the Boston...ter. BMC,s Pepper Center is one of only 11 Pepper ...Older Americans Independence Center Program was es....S. senator from Florida. During his five decades ...
Breaking Medicine News(10 mins):Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2Health News:Boston Medical Center receives $5.8m grant 2
...the Harvard Medical School, Boston, has confirmed ...k of breast cancer.// A study of more than 100,00... or miscarriage were no more likely to have breast... the study. The findings fit in with a 2003 repor...
...ording to the recent communiqué from US drug revie...promises to contain the HIV virus when used in com...stion named as maraviroc may find a prominent plac...s power to impede the CCR5 co-receptor, the main r...
...l meeting organized to thrash out issues pertainin...opportunity to focus attention on a burning issue ...ies. Amongst the Inuit population of Nunavik, Cana... time high of seven times the national rate- 11.3 ...
...e localized two new genes that are associated with...childhood, according to a study. // “Identifying ...mprove the understanding, treatment and even preve...uthor Rima Nabbout, MD, PhD, of the French Institu...
Other Medicine News:Health News:Abortions Do Not Raise Risk of Breast Cancer 2Health News:Suicide - Aboriginal Communities Take Stock of the Killing Numbers 2
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
Medicine Products: